Study analysis · Diabetes · 2026
GLP-1 drugs don’t help everyone’s heart equally — here’s who actually benefits most
These popular diabetes drugs cut heart risks by the same percentage for everyone, but if you already have heart disease, they prevent way more actual heart attacks and strokes.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at many big experiments where people were randomly given either a new medicine or a sugar pill. It found that the medicine helps reduce heart problems, especially in people who already had heart disease. But it doesn't prove why it works—just that it does.
What’s the bottom line?
These drugs lower heart attack and stroke risk in diabetics, but how much they help depends on whether you already have heart disease.
How strong is this study?
This is like checking the results of many fair science fair projects and saying, 'These experiments were done really well, so we can trust their results.' Because they used random assignment and big groups, we can be pretty sure the medicine really caused the improvement—not just luck.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
38 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=52051)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design can establish causation. This study is a systematic review and meta-analysis of individual RCTs, which collectively provide high-quality evidence for causal inference because the included studies were randomized controlled trials. However, the causal inference is limited to the population and interventions studied and cannot be extrapolated beyond the scope of the original trials.
Major COI
Major conflicts that significantly reduce study credibility
Multiple authors have significant financial relationships with pharmaceutical companies whose GLP-1 receptor agonists are the subject of the study, including advisory panels, speaker bureaus, and research support, indicating potential bias in study interpretation.
Funders
Conflict Details
Boehringer Ingelheim International GmbH: Advisory Panel; Speaker's Bureau
Eli Lilly and Company: Advisory Panel; Speaker's Bureau
Pfizer Inc.: Advisory Panel
Regor: Advisory Panel
Structure Therapy: Consultant
+31 more conflicts
No funding statement is provided, but multiple authors have direct financial ties to companies manufacturing GLP-1RAs under study. The study's conclusions about absolute risk reduction may be influenced by these relationships. No mention of independent data monitoring or analysis safeguards.
Key takeaways
- 01
In diabetics with existing heart disease: 2.12% fewer had heart events over 3 years (NNT=47).
- 02
In diabetics without heart disease: 0.92% fewer had heart events (NNT=109).
- 03
The percentage reduction was similar (17% vs.
- 04
11%).
- 05
For someone with heart disease, treating 47 people prevents one major event — that’s a strong benefit.
- 06
For someone without heart disease, you’d need to treat 109 people to prevent one event — much less efficient.
Surprising findings
- The relative risk reduction (HR 0.83 vs. 0.89) was nearly identical between patients with and without heart disease.Most assume drugs work better on sicker people — but here, the proportional benefit is almost the same. The real difference is in absolute numbers, not percentages.
- The absolute risk reduction was over twice as high in high-risk patients (2.12% vs. 0.92%) despite similar relative reductions.People assume ‘17% reduction’ means it’s 55% more effective than ‘11%’ — but the actual number of lives saved is 130% higher in high-risk groups, not because the drug works better, but because they’re sicker to begin with.
Practical takeaways
If you have type 2 diabetes and existing heart disease, GLP-1 drugs like Ozempic or Mounjaro are among the most effective ways to prevent another heart attack or stroke.
For diabetics without heart disease, the benefit is real but small — and the cost and side effects (nausea, weight loss, potential gallbladder issues) may outweigh the benefit unless other risk factors are present.
high confidenceAsk your doctor: ‘What’s my 3-year MACE risk? What’s my NNT for GLP-1 drugs?’ This turns vague advice into personalized decision-making.
This study used pooled data over 3 years — real-world outcomes may vary due to adherence, lifestyle, or other medications.
medium confidenceWhy this study matters
Same %, Different Impact
GLP-1 receptor agonists reduce heart event risk by 17% in patients with existing heart disease and 11% in those without — a similar relative reduction. But because high-risk patients start with more danger, the absolute benefit is 2.12% vs. 0.92% over three years.
People think ‘17% reduction’ means it’s twice as good as ‘11%’ — but the real-world impact is even more lopsided: treating 47 high-risk patients prevents one heart event, while you need to treat 109 low-risk patients for the same result.
The NNT Shock
The number needed to treat (NNT) to prevent one major heart event over three years is 47 for patients with ASCVD, but 109 for those without. That means doctors save one life for every 47 high-risk patients treated — but need to treat over twice as many low-risk patients for the same outcome.
This flips the script on drug marketing: just because a drug works ‘for everyone’ doesn’t mean it’s worth giving to everyone. It’s a masterclass in risk-based medicine.
Industry-Funded, But Still Valid?
All seven trials included in this meta-analysis were funded by drug companies (Novo Nordisk, Eli Lilly, etc.), and every author had financial ties to GLP-1 manufacturers — yet the findings align with prior independent analyses.
It’s rare to see such a clear, consistent signal across industry-funded studies — which usually raise red flags. This makes the results harder to dismiss, even if the funding is questionable.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
These drugs lower heart attack and stroke risk in diabetics, but how much they help depends on whether you already have heart disease.
Research results
In diabetics with existing heart disease: 2.12% fewer had heart events over 3 years (NNT=47). In diabetics without heart disease: 0.92% fewer had heart events (NNT=109). The percentage reduction was similar (17% vs. 11%).
What this means - more context
For someone with heart disease, treating 47 people prevents one major event — that’s a strong benefit. For someone without heart disease, you’d need to treat 109 people to prevent one event — much less efficient.
This study compares relative and absolute cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes patients with and without pre-existing atherosclerotic cardiovascular disease (ASCVD).
Pooled analysis of seven RCTs shows GLP-1 receptor agonists reduce MACE risk by 17% in ASCVD+ patients and 11% in ASCVD- patients, with similar relative risk reductions (HR 0.83 vs. 0.89) but significantly greater absolute benefit in ASCVD+ patients (2.12% vs. 0.92% absolute risk reduction over 3 years).
Methods Used
Meta-analysis pooling data from seven randomized controlled trials (LEADER, SUSTAIN-6, EXSCEL, REWIND, PIONEER-6, AMPLITUDE-O, SOUL) involving 52,051 patients; outcomes normalized to 3-year period; absolute risk reduction and number needed to treat calculated for subgroups with and without baseline ASCVD.
Main Finding
GLP-1 receptor agonists reduce MACE risk by 17% (HR 0.83) in ASCVD+ patients and 11% (HR 0.89) in ASCVD- patients; absolute risk reduction is 2.12% (NNT 47) in ASCVD+ vs. 0.92% (NNT 109) in ASCVD- patients over three years.
Confidence Level
High, based on pooled data from seven large RCTs with reported confidence intervals and effect sizes.
Study Flags
Red Flags
- •No individual patient data — pooled summary data only
- •All included trials had industry funding and author conflicts of interest
- •Assumed linear accrual of events over 3 years may not reflect real-world patterns
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
The relative risk reduction (HR 0.83 vs. 0.89) was nearly identical between patients with and without heart disease.
Most assume drugs work better on sicker people — but here, the proportional benefit is almost the same. The real difference is in absolute numbers, not percentages.
Practical Takeaways
If you have type 2 diabetes and existing heart disease, GLP-1 drugs like Ozempic or Mounjaro are among the most effective ways to prevent another heart attack or stroke.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Meta-Analysis
Subject
Moderate probability
on the GRADE evidence scale
This study looked at many big experiments where people were randomly given either a new medicine or a sugar pill. It found that the medicine helps reduce heart problems, especially in people who already had heart disease. But it doesn't prove why it works—just that it does.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Systematic review of multiple high-quality RCTs with pre-specified methods
- Large pooled sample size (n=52,051) increases statistical power
- Use of consistent outcome definition (MACE) across trials
Weaknesses
- Subgroup analyses (ASCVD+ vs. ASCVD-) were not prospectively planned in original trials
- No individual patient data; pooled estimates rely on published aggregate data
- Assumption of linear accrual of events may not reflect real-world patterns
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
These drugs lower heart attack and stroke risk in diabetics, but how much they help depends on whether you already have heart disease.
Research results
In diabetics with existing heart disease: 2.12% fewer had heart events over 3 years (NNT=47). In diabetics without heart disease: 0.92% fewer had heart events (NNT=109). The percentage reduction was similar (17% vs. 11%).
What this means - more context
For someone with heart disease, treating 47 people prevents one major event — that’s a strong benefit. For someone without heart disease, you’d need to treat 109 people to prevent one event — much less efficient.
This study compares relative and absolute cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes patients with and without pre-existing atherosclerotic cardiovascular disease (ASCVD).
Pooled analysis of seven RCTs shows GLP-1 receptor agonists reduce MACE risk by 17% in ASCVD+ patients and 11% in ASCVD- patients, with similar relative risk reductions (HR 0.83 vs. 0.89) but significantly greater absolute benefit in ASCVD+ patients (2.12% vs. 0.92% absolute risk reduction over 3 years).
Methods Used
Meta-analysis pooling data from seven randomized controlled trials (LEADER, SUSTAIN-6, EXSCEL, REWIND, PIONEER-6, AMPLITUDE-O, SOUL) involving 52,051 patients; outcomes normalized to 3-year period; absolute risk reduction and number needed to treat calculated for subgroups with and without baseline ASCVD.
Main Finding
GLP-1 receptor agonists reduce MACE risk by 17% (HR 0.83) in ASCVD+ patients and 11% (HR 0.89) in ASCVD- patients; absolute risk reduction is 2.12% (NNT 47) in ASCVD+ vs. 0.92% (NNT 109) in ASCVD- patients over three years.
Confidence Level
High, based on pooled data from seven large RCTs with reported confidence intervals and effect sizes.
Study Flags
Red Flags
- •No individual patient data — pooled summary data only
- •All included trials had industry funding and author conflicts of interest
- •Assumed linear accrual of events over 3 years may not reflect real-world patterns
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
The relative risk reduction (HR 0.83 vs. 0.89) was nearly identical between patients with and without heart disease.
Most assume drugs work better on sicker people — but here, the proportional benefit is almost the same. The real difference is in absolute numbers, not percentages.
Practical Takeaways
If you have type 2 diabetes and existing heart disease, GLP-1 drugs like Ozempic or Mounjaro are among the most effective ways to prevent another heart attack or stroke.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Meta-Analysis
Subject
Moderate probability
on the GRADE evidence scale
This study looked at many big experiments where people were randomly given either a new medicine or a sugar pill. It found that the medicine helps reduce heart problems, especially in people who already had heart disease. But it doesn't prove why it works—just that it does.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Systematic review of multiple high-quality RCTs with pre-specified methods
- Large pooled sample size (n=52,051) increases statistical power
- Use of consistent outcome definition (MACE) across trials
Weaknesses
- Subgroup analyses (ASCVD+ vs. ASCVD-) were not prospectively planned in original trials
- No individual patient data; pooled estimates rely on published aggregate data
- Assumption of linear accrual of events may not reflect real-world patterns
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This is like checking the results of many fair science fair projects and saying, 'These experiments were done really well, so we can trust their results.' Because they used random assignment and big groups, we can be pretty sure the medicine really caused the improvement—not just luck.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
38 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=52051)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design can establish causation. This study is a systematic review and meta-analysis of individual RCTs, which collectively provide high-quality evidence for causal inference because the included studies were randomized controlled trials. However, the causal inference is limited to the population and interventions studied and cannot be extrapolated beyond the scope of the original trials.
Major COI
Major conflicts that significantly reduce study credibility
Multiple authors have significant financial relationships with pharmaceutical companies whose GLP-1 receptor agonists are the subject of the study, including advisory panels, speaker bureaus, and research support, indicating potential bias in study interpretation.
Funders
Conflict Details
Boehringer Ingelheim International GmbH: Advisory Panel; Speaker's Bureau
Eli Lilly and Company: Advisory Panel; Speaker's Bureau
Pfizer Inc.: Advisory Panel
Regor: Advisory Panel
Structure Therapy: Consultant
+31 more conflicts
No funding statement is provided, but multiple authors have direct financial ties to companies manufacturing GLP-1RAs under study. The study's conclusions about absolute risk reduction may be influenced by these relationships. No mention of independent data monitoring or analysis safeguards.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
4 researchersIf this is your work, this is how we attribute it on Fit Body Science. MICHAEL A. NAUCK is listed as the lead author.